6 Things to Know About Medtronic’s Cyberattack

Katie Adams / medcitynews - Medtronic suffered a cyberattack on its corporate IT systems. The incident highlights growing cybersecurity risks in the medtech sector, with cybergangs increasingly using phishing and other human-engineering tactics to gain access to data.The post 6 Thin…

AI Summary: Medtronic reported an IT systems breach following a cyberattack, prompting an internal probe and operational mitigation efforts. The company is assessing clinical and supply impacts, notifying stakeholders, and coordinating with cybersecurity authorities — a reminder that even medtech giants are not immune to the digital snarls that can ripple through patient care and profits.

WHO approves first malaria treatment for infants

medicalxpress - The World Health Organization announced Friday that it had given prequalification approval to a malaria treatment for newborns and infants for the first time.

AI Summary: The World Health Organization has cleared the first malaria treatment specifically for infants, granting prequalification that paves the way for broader procurement and use in endemic countries. Regulators' sign-off targets a vulnerable age group long underserved by effective pediatric therapies, potentially speeding distribution through global health channels and donor programs.

Baby food brand HiPP recalls jars in Austria after samples test positive for rat poison

abcnews - HiPP is recalling some baby food jars in Austria after samples tested positive for rat poison in Austria, Slovakia and the Czech Republic

AI Summary: Austrian health authorities have ordered a recall of specific HiPP baby food jars after lab tests detected contamination with a rodent poison. Retailers pulled the affected batches, parents are being urged to check product codes and discard implicated jars, and investigators are tracing how the contamination occurred while monitoring for any reported illnesses.

FDA updates mifepristone safety study status

Ella Jeffries / beckershospitalreview - The FDA updated its mifepristone guidance, detailing ongoing work on a safety study and the current status of the drug’s Risk Evaluation and Mitigation Strategy program. According to an April 8 news release, the agency said it is still collecting and eval…

AI Summary: The FDA updated the safety review status for mifepristone, yet the regulatory change hasn’t translated into widespread retail availability. Many community pharmacies are still hesitant to dispense the drug due to logistical, legal and reputational concerns, leaving access limited despite federal moves intended to broaden distribution — so yes, policy changed, but practice lagged.

FDA to review whether to allow more access to certain peptides

medicalxpress - The U.S. Food and Drug Administration (FDA) will soon review whether certain peptides should be allowed in customized medications made by compounding pharmacies.

AI Summary: The FDA is moving toward expanding access to certain compounded peptides, opening a regulatory review that could loosen limits on how pharmacies and clinics obtain and prepare these popular therapies. The review balances potential patient demand and shortages against safety and quality-control concerns, putting compounding practices squarely under the spotlight.

Cencora acquiring EyeSouth Partners' retina business for $1.1B

fiercehealthcare - EyeSouth Partners' retina specialists will join Cencora's Retina Consultants of America, a management services organization that already boasts the country's largest network of retina centers.

AI Summary: Cencora has agreed to acquire EyeSouth Partners’ retina business for roughly $1.1 billion, strengthening its position in specialty ophthalmology services. The deal transfers a network of retinal care assets and aims to integrate retina-focused clinical operations and distribution under Cencora’s broader eye‑care strategy.

TerraPower Isotopes Invests $450M in Actinium-225 Production Facility

oncodaily - TerraPower Isotopes (TPI), the Bill Gates-founded nuclear science company, unveiled plans on March 17, 2026 to invest $450 million in a state-of-the-art actinium-225 (Ac-225) manufacturing facility in Philadelphia’s Bellwether District. The 250,000-square…

AI Summary: TerraPower announced a $450 million investment to construct a commercial Actinium‑225 production facility to supply alpha‑emitting radioisotopes for targeted cancer therapies. The plan tackles chronic supply shortages, strengthens domestic radiopharmaceutical capacity and positions the company at the center of growing demand for targeted‑alpha therapeutics — and yes, investors are watching.

New EPA rule could loosen limits on medical device sterilization gas emissions

medicalxpress - The U.S. Environmental Protection Agency (EPA) is proposing to loosen limits on emissions of ethylene oxide, a gas used to sterilize many medical devices that is also linked to cancer.

AI Summary: The Environmental Protection Agency proposed easing limits on ethylene oxide — the gas hospitals use to sterilize medical devices — arguing the change protects the medical supply chain. Public‑health experts and community advocates warn long‑term exposure raises cancer risks and say rolling back 2024 safeguards could shift the burden onto nearby residents.

‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up

Marissa Plescia / medcitynews - Novo Nordisk dropped its lawsuit against Hims & Hers and launched a new collaboration. The deal is advantageous for both companies, experts say.The post ‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up appeared first on MedCity News.

AI Summary: Novo Nordisk has dropped its legal fight with Hims & Hers and struck a business-friendly truce: Hims will sell Novo’s branded weight‑loss medications on its platform. The abrupt move turns courtroom theatrics into commercial collaboration, smoothing distribution while leaving regulators and competitors to enjoy the schadenfreude.

6 Things to Know About Stryker’s Cyberattack

Katie Adams / medcitynews - Stryker was hit by a cyberattack this week that knocked out its internal systems worldwide and caused delays to order processing and manufacturing. An Iran-linked group has claimed responsibility for the attack, but the full impact remains unclear.The pos…

AI Summary: A worldwide cyberattack knocked out Stryker’s enterprise Microsoft environment, wiping access to key internal systems and forcing hospitals and manufacturers to scramble for workarounds. The company is issuing platform‑specific updates while investigators link the intrusion to a pro‑Iran actor, leaving supply chains and surgical workflows nervously improvising.